According to our earlier studies, tissue plasminogen activator (tPA), the admitted therapy in stroke patients, promotes TXNIP-NLRP3 inflammasome activation in hyperglycemic stroke mouse model (Ismael et al., 2020). Here, TXNIP is linked to stroke disorder.